BioSpace News Archive

NeuroOne Medical Technologies Corporation today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc.

Smiths Medical issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with specific Level 1® H-2 Pressure Chambers used with the Level 1 Fast Flow Fluid Warmers.

GLO Pharma, the parent company of breakthrough subtopical skincare brand Ourself, announces the promotion of Vimla Black-Gupta to CEO of Ourself.

NEW ‘Transparency Talks’ With Pfizer and Global Pricing Innovations Help Pharmaceutical Companies Stay Compliant With Drug Pricing Model N, Inc., the leader in revenue optimization and compliance, announced the launch of Transparency Talks, a new, three-part education series for pharmaceutical companies that tackles the topic of price transparency regulations for prescription drugs.

Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it has received both federal registration and state licensing to begin commercial production of its new KinetiX™ RTA Platform brand of pre-filled syringes.

Immunologix Laboratories announced today that Dr. Corinna Fiorotti has been appointed Chief Commercial Officer.

The U.S. pharmaceutical analytical testing outsourcing market was surpassed at USD 3.5 billion in 2021 and is expected to hit around USD 7.2 billion by 2030, growing at a CAGR of 8.34% from 2022 to 2030.

Black Diamond Therapeutics, Inc. today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will participate in a panel discussion titled, Bullseye - Targeted Oncology - Quanta of Targets, at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022.

Neoleukin Therapeutics, Inc., today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern.